According to the relevant regulations of the National Health Insurance Administration, all provinces will gradually digest the supplementary medical insurance catalogue of the original province, and it is planned that all of them will be digested by the end of 2022, and the national drug catalogue
will be unified next year.
However, it is worth noting that the policy also leaves a mandate for local medical insurance bureaus, that is, ethnic medicines, Chinese medicine tablets, and preparations prepared by medical institutions can be included in the local catalog
.
Therefore, many places are actively improving and adjusting the medical insurance catalogue
under this policy.
Recently, Qinghai Province announced the preliminary examination results of 27 ethnic medicines included in the Qinghai Provincial Medical Insurance Drug List
.
The announcement shows that according to the adjustment provisions of the relevant ethnic drug list in Qinghai Province, the provincial medical insurance bureau conducted a preliminary review of the ethnic drugs declared for inclusion in the list, and publicized
the list of drugs that passed the preliminary review.
The public notice period is 7 days: November 4 to November 10
.
It is understood that the conditions for the declaration of ethnic medicines in Qinghai Province need to comply with the provisions of Article 7 of the Implementation Measures for the Administration of Drugs of Basic Medical Insurance in Qinghai Province, and off-list drugs with one of the following circumstances can be declared to participate in the adjustment
of the list of ethnic medicines in 2022.
For example, as of July 31, 2022, ethnic drugs approved by the national drug administration and within the validity period of the drug registration certificate; Priority will be given to ethnic medicines
that have been included in the Qinghai Provincial Essential Medicines List.
After combing, it was found that among the 27 ethnic medicines that passed the preliminary examination this time, 16 were Tibetan medicines and 11 were Mongolian medicines, of which 18 were exclusive varieties
.
At present, in addition to Qinghai Province, Gansu, Qinghai, Yunnan, Guangxi and other places have also clearly supplemented ethnic medicines
.
Among them, on August 17, the Guangxi Bureau of Traditional Chinese Medicine issued the Notice on Publishing the List of Guangxi Ethnic Medicines (First Batch), which identified 218 drugs as the first batch of Guangxi ethnic medicines
.
Prior to this, the Anhui Provincial Medical Insurance Bureau issued the Notice on Adjusting the List of Outpatient Chronic Diseases and Outpatient Drugs of Basic Medical Insurance, which clearly expanded the coverage of outpatient chronic diseases and further reduced the burden
of family medical expenses of insured patients.
According to the notice, from December 1, 2022, the province will uniformly include progressive muscular dystrophy, Fabry disease, Huntington's disease, neuromyelitis optica, spinal bulbar muscular atrophy (Kennedy's disease), thyretin amyloidosis cardiomyopathy, hereditary angioedema and other 7 diseases into the coverage of employee medical insurance and resident medical insurance chronic disease outpatient coverage
.
It is worth mentioning that in early October, the Anhui Medical Insurance Bureau also issued the Notice on Printing and Distributing Preparations and New Chinese Medicine Pieces <from Medical Institutions in Anhui Province into the List of Varieties of Funds (Trial) > (Draft for Comments) (hereinafter referred to as the Draft for Comments), which intends to include 81 newly added Chinese medicine pieces such as vine pear root, Fushen and gynostemma into the payment scope
of the provincial basic medical insurance, work-related injury insurance and maternity insurance fund.
The Draft clarifies that the 81 newly added Chinese medicine pieces should, in principle, refer to the management of Class A drugs, and there is no self-payment ratio
for individuals in advance.
For some Chinese medicine pieces with higher prices, various localities can determine the proportion
of individual self-payment according to the fund's affordability.
From the above point of view, all localities are continuing to improve the adjustment mechanism of the medical insurance drug list, comprehensively considering the balanced development of the direction of drug innovation and the drug needs of insured personnel and the affordability of medical insurance funds, and carry out the catalog access work
more scientifically and reasonably.
In this context, the industry expects that more high-quality and low-cost drugs will enter medical insurance, and the protection level of the majority of insured patients will be further improved
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
